Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
- Conditions
- HER2-negative Breast CancerAdvanced Breast Cancer
- Interventions
- Drug: Organoid-guided treatmentDrug: Anthracycline
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 252
- Registration Number
- NCT06102824
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-12-12
- Target Recruit Count
- 376
- Registration Number
- NCT06081959
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 400
- Registration Number
- NCT06079983
- Locations
- 🇨🇳
Jilin Provincial Cancer Hospital, Changchun, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, China
🇨🇳Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
- Conditions
- Refractory Solid Tumors
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT06006273
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
- Conditions
- HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2023-07-14
- Target Recruit Count
- 78
- Registration Number
- NCT05945368
- Locations
- 🇨🇳
LI YuDong, Guanzhou, Guangdong, China
Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 122
- Registration Number
- NCT05833919
- Locations
- 🇮🇹
Università Campus Biomedico, Roma, Italy
🇮🇹Istituto Nazionale dei Tumori - Fondazione G. Pascale, Napoli, Italy
🇮🇹ASUFC P.O. "Santa Maria della Misericordia", Udine, Italy
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Conditions
- Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)Platinum-resistant Ovarian Cancer (PROC)Hepatocellular Carcinoma (HCC)Colorectal Cancer (CRC)HER2 Negative Breast CancerCutaneous MelanomaRenal Cell Carcinoma (RCC)
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- GI Innovation, Inc.
- Target Recruit Count
- 358
- Registration Number
- NCT05824975
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Minnesota, Rochester, Minnesota, United States
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
- Conditions
- Advanced Breast CancerBreast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 14
- Registration Number
- NCT05810870
- Locations
- 🇪🇸
Hospital Universitario Clínico San Cecilio de Granada, Granada, Andalucia, Spain
🇪🇸Hospital Universitario Virgen del Rocio, Sevilla, Andalucia, Spain
🇪🇸Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Drug: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabineDrug: nab-paclitaxel, with maintenance of capecitabineDrug: VEGFR and TPC
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 192
- Registration Number
- NCT05806060
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
- Conditions
- Ovarian CarcinosarcomaUterine Carcinosarcoma
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2025-02-04
- Target Recruit Count
- 30
- Registration Number
- NCT05619913
- Locations
- 🇦🇺
Prince of Wales Hospital, Randwick, New South Wales, Australia
🇬🇧Imperial College London, London, United Kingdom
🇦🇺Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.